Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,994 total articles
Collegium Pharmaceutical, Inc. reported a 9% year-over-year increase in quarterly net revenues to $193.5 million for Q1 2026, driven by a 36% growth in JORNAY PM sales. The company is on track to acquire AZSTARYS, a complementary ADHD treatment, expected in Q2 2026, which will enhance its ADHD portfolio and expand growth potential. Pain portfolio r…
Stardust Power Inc., a US-based developer of battery-grade lithium carbonate, announced it will release its Q1 2026 financial results on May 14, 2026, after market close. The company will host a conference call the same day to discuss the results and provide updates on its strategic lithium refinery project in Oklahoma aiming to support America's e…
urban-gro, Inc., via its subsidiary Innovative Production Group FZ, LLC (IPG), announces its commercial involvement in the Lanka Premier League Season 6, scheduled for July-August 2026 in Sri Lanka. The company highlights the opening of the foreign player registration portal on May 8, 2026, and emphasizes its role as a sports, media, and experienti…
Ascendis Pharma reported strong financial results for Q1 2026, driven by significant revenue growth from its commercial products, especially YORVIPATH, which generated €197 million. The company successfully launched YUVIWEL in the U.S. with over 60 patient enrollments since April. The company plans further clinical trials and market expansions and …
Plus Therapeutics announced that its subsidiary CNSide Diagnostics has been approved for Medicare enrollment, allowing billing for its CNSide CSF Assay diagnostic test for CNS cancers. This milestone facilitates access to Medicare beneficiaries, supports reimbursement processes, and strengthens commercialization efforts with national and regional p…
Palvella Therapeutics reported strong Q1 2026 results highlighting positive Phase 3 data for QTORIN™ rapamycin in microcystic lymphatic malformations, an FDA Pre-NDA meeting scheduled for Q2 2026, and a planned NDA submission in H2 2026. The company also secured $230 million in oversubscribed equity financing to fund commercialization and pipeline …
Lexicon Pharmaceuticals reported a significant reduction in net loss for Q1 2026, driven by milestone payments and controlled expenses. The company is advancing pivotal clinical trials for sotagliflozin in hypertrophic cardiomyopathy and type 1 diabetes, with anticipated regulatory submissions and approvals within 2026. Licensing agreements with No…
Harvard Bioscience, Inc., a developer and manufacturer of life science technologies, announced that its CEO John Duke and CFO Mark Frost will participate in two upcoming virtual investor conferences in May 2026, including the Sidoti Micro Cap Conference and the Benchmark Healthcare House Call Virtual Conference. The company will provide a live webc…
Kelly Services reported a 10.7% decline in Q1 2026 revenue to $1.0 billion, impacted by weaker demand in certain segments and discrete customer impacts. The company posted a $5.1 million operating loss but an adjusted operating income of $4.1 million. Cost reduction efforts led to a 10.3% decline in SG&A expenses. Kelly affirmed its outlook for gra…
QuasarEdge Acquisition Corporation (NYSE: QRED) has signed a non-binding letter of intent to acquire Robseek Intelligence Inc., an infrastructure platform company focused on AI-driven device distribution and data services primarily in the Middle East. The proposed transaction involves a share-for-share exchange, aiming to bring Robseek public throu…
Evaxion A/S, a clinical-stage TechBio company specializing in AI-based vaccine development, announced its first quarter 2026 financial results alongside key business updates. The company demonstrated strong progress with new data validating their AI-Immunology™ platform’s high precision in cancer vaccine target recognition and scalability in gliobl…
EDAP TMS SA reported strong financial results for Q1 2026, driven by a record $11.6 million in High-Intensity Focused Ultrasound (HIFU) revenue, representing 78% growth year-over-year. The company achieved its seventh consecutive quarter of HIFU revenue growth, with key markets in the U.S. and Europe expanding capital sales of the Focal One Robotic…
Alterity Therapeutics will present significant clinical data and updates on its lead drug ATH434 targeting Multiple System Atrophy (MSA) at several international medical conferences in May 2026. The presentations include promising Phase 2 trial results and plans for a Phase 3 pivotal study, underscoring the company's advancement in developing disea…
Entrada Therapeutics announced positive topline results from Cohort 1 of its ELEVATE-44-201 Phase 1/2 study for Duchenne muscular dystrophy (DMD), demonstrating favorable safety, tolerability, and early functional benefits. The company maintains a strong cash position with $255 million, providing runway into Q3 2027, and plans upcoming data release…
Gilat Satellite Networks Ltd. announced that their CFO, Gil Benyamini, will present and attend the upcoming 21st Annual Needham Technology, Media, & Consumer 1x1 Conference and the 27th Annual Oppenheimer Israel Conference. The company is a leading provider of satellite communications technology and solutions, serving commercial and defense sectors…
Xometry announced record Q1 2026 financial results with 36% revenue growth to $205 million driven by 40% marketplace revenue growth. The company improved Adjusted EBITDA to $10.5 million and expanded active buyers and accounts with significant spend. A strategic partnership with Siemens includes a $50 million equity purchase, reinforcing confidence…
Iovance Biotherapeutics announced robust first quarter 2026 financial results, with total product revenue rising approximately 45% year-over-year to $71 million. The company provided strong guidance for Q2 and full year 2026 revenues, driven primarily by growth in Amtagvi sales. Clinical progress includes a 40% confirmed objective response rate in …
Appian Corporation announced its financial results for Q1 2026, showing significant growth in cloud subscription revenue by 25% year-over-year, total revenue up 21%, and a turnaround to GAAP operating income from a loss in the previous year. The company also raised guidance for 2026, projecting continued double-digit growth in cloud subscriptions a…
Resolute Holdings Management, Inc. reported robust first quarter 2026 financial results, posting a net income per share of $7.19, a substantial improvement from a loss last year. Non-GAAP Fee-Related Earnings per share rose to $0.69, driven by new management agreements and organic fee growth. The company also repurchased $38 million in shares, high…
GPGI, Inc. announced its Q1 2026 results, showing a 3% increase in pro forma adjusted net sales to $421.2 million and record sales growth at CompoSecure driven by the Resolute Operating System (ROS). However, Husky Technologies faced unexpected headwinds from volatile oil and resin prices and tariff uncertainty, resulting in a 16% decline in pro fo…
Invivyd, a US-based biopharmaceutical company focused on antiviral monoclonal antibodies, announced it will hold a webcast conference call on May 14, 2026 to discuss its first quarter financials and provide a corporate update. The company recently received FDA emergency use authorization for a monoclonal antibody targeting SARS-CoV-2, underscoring …
Lifetime Brands, Inc. reported Q1 2026 financial results that beat consensus estimates with 2.4% net sales growth and improved EBITDA, driven by strong performance in Home Solutions and kitchen tools segments. The company implemented early pricing strategies and cost structure actions that are now yielding benefits. Lifetime Brands also commissione…
WW International, Inc. announced its Q1 2026 financial results with total subscribers at 2.7 million and clinical subscribers increasing 46% year-over-year. The company reported $168 million in revenue, with clinical subscription revenue up 32%. WW reaffirmed its full-year 2026 revenue and adjusted EBITDA guidance and announced a fully subscribed d…
Climb Bio, a clinical-stage biotech company focused on immune-mediated diseases, reported its Q1 2026 financials, showing a net loss reduced from last year and a strong cash position bolstered by a recent $110 million private placement. The company provided updates on its two clinical-stage programs—budoprutug and CLYM116—highlighting positive Phas…
Akebia Therapeutics reported Q1 2026 financial results highlighted by a 60% increase in patients treated with Vafseo and Q1 net product revenues of $52.0 million, driven by growing adoption in dialysis-related anemia treatment. The company advanced clinical trials for rare kidney diseases and expects pivotal data for Vafseo dosing regimens by early…
